The logo of Teva Pharmaceutical Industries is seen during a FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen Post navigation Previous: US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute